Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4+T Cells of Patients With Relapsing-Remitting Multiple Sclerosis

Journal of Immunology Research - Egypt
doi 10.1155/2014/897249
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Hindawi Limited

Related search

Natalizumab: A New Treatment for Relapsing Remitting Multiple Sclerosis

Therapeutics and Clinical Risk Management
Chemical HealthPharmacologySafetyMedicineToxicologySafety ResearchPharmaceutics
2007English

Cognitive Profile of Patients With Relapsing Remitting Multiple Sclerosis

Arquivos de Neuro-Psiquiatria
Biological PsychiatryNeurology
1999English

Real-Life Effectiveness of Natalizumab in Relapsing-Remitting Multiple Sclerosis (Rrms): A Registry Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Efficacy of Natalizumab and Fingolimod in Relapsing Remitting Multiple Sclerosis in Real World Clinical Setting

Journal of Neurology & Neurophysiology
2015English

Pnd12 - Natalizumab Versus Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Progressive Gray Matter Damage in Patients With Relapsing-Remitting Multiple Sclerosis

Archives of Neurology
2005English

Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis

Neurotherapeutics
NeurologyPharmacology
2017English

Long-Term Safety and Efficacy of Natalizumab in Relapsing-Remitting Multiple Sclerosis: Impact on Quality of Life

Patient Related Outcome Measures
2014English

Long-Term Evaluation of NEDA-3 Status in Relapsing-Remitting Multiple Sclerosis Patients After Switching From Natalizumab to Fingolimod

Therapeutic Advances in Neurological Disorders
NeurologyPharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy